- Astellas' XTANDI™ (Enzalutamide) Granted European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting
- Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs
- China's National Medical Products Administration Accepts Astellas and Pfizer's Supplemental Biologics License Application for enfortumab vedotin with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
- Astellas Receives Permanent J-code for IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy
- Astellas' VYLOY™ (zolbetuximab) Approved in Japan for Treatment of Gastric Cancer
- Astellas Receives Positive CHMP Opinion for XTANDI™ in Additional Recurrent Early Prostate Cancer Treatment Setting
- FDA Grants Orphan Drug and Pediatric Exclusivities for CRESEMBA® (isavuconazonium sulfate) for Invasive Aspergillosis and Invasive Mucormycosis in Children
- Astellas Initiates Phase 3 Clinical Studies of Fezolinetant for VMS Associated with Menopause in Japan
- Astellas Names Michael Petroutsas as Head of US Commercial
- Astellas and Kelonia Therapeutics Enter into Research and License Agreement to Develop Novel Immuno-Oncology Therapeutics
More ▼
Key statistics
On Friday, Astellas Pharma Inc (4503:TYO) closed at 1,506.00, 5.61% above its 52-week low of 1,426.00, set on Apr 16, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1,482.00 |
---|---|
High | 1,506.00 |
Low | 1,446.00 |
Bid | 1,503.00 |
Offer | 1,506.50 |
Previous close | 1,455.00 |
Average volume | 11.97m |
---|---|
Shares outstanding | 1.81bn |
Free float | 1.81bn |
P/E (TTM) | 594.95 |
Market cap | 2.66tn JPY |
EPS (TTM) | 2.47 JPY |
Annual div (ADY) | 65.00 JPY |
---|---|
Annual div yield (ADY) | 4.47% |
Div ex-date | Mar 28 2024 |
Div pay-date | Jun 03 2024 |
Data delayed at least 20 minutes, as of Apr 26 2024 07:00 BST.
More ▼